Max Health is pleased to announce that it has received approval from Medsafe for the registration of Ethinylestradiol 30mcg and Levonorgestrel 150mcg (branded as Lynley™) oral contraceptive for use in New Zealand. This registration is effective from 11 March 2021.
This product is part of a collaboration with our Australian partner, Generic Health, and is manufactured by leading international generic pharmaceutical company, Lupin. We await a decision from PHARMAC regarding potential reimbursement of the product.